Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.

Author: ChuLarry F, ClarkJ David, D'ArcyNicole, EnciscoEllen M, ErlendsonMatthew J, PeltzGary, Rincon-CruzLorena, YuJeffrey J

Paper Details 
Original Abstract of the Article :
BACKGROUND: Treatments for reducing opioid withdrawal are limited and prone to problematic side effects. Laboratory studies, clinical observations, and limited human trial data suggest 5-HT3-receptor antagonists and antihistamines may be effective. OBJECTIVES: This double-blind, crossover, placebo-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/27712113

データ提供:米国国立医学図書館(NLM)

Combating Opioid Withdrawal: A Journey Through the Desert of Addiction

Imagine a camel caravan abruptly halted in the desert, facing the brutal withdrawal symptoms of opioid dependence. That’s the harsh reality for many individuals struggling with addiction. This study, like a compassionate desert guide, explores the potential benefits of palonosetron and hydroxyzine in reducing the severity of opioid withdrawal.

The researchers, like explorers testing new routes, conducted a double-blind, crossover, placebo-controlled study. The results show that pretreatment with palonosetron significantly reduced the objective signs of opioid withdrawal, like finding a refreshing oasis in a parched land. Adding hydroxyzine to the treatment further reduced withdrawal severity, offering additional relief.

Finding Relief in the Desert: New Hope for Opioid Withdrawal

This study, like a beacon shining through the darkness, offers a potential solution for managing the distressing symptoms of opioid withdrawal. The findings suggest that 5-HT3 receptor antagonists, like a well-stocked caravan, can provide valuable support during this challenging process.

Navigating the Desert of Addiction: A Path to Recovery

Opioid withdrawal, like a treacherous desert trek, can be an intensely difficult experience. However, with continued research and the development of new treatment options, we can provide individuals with the resources and support they need to navigate this challenging journey and achieve a path to recovery.

Dr. Camel's Conclusion

This study, like a caravan sharing its wisdom, offers hope for individuals struggling with opioid withdrawal. The findings suggest that palonosetron and hydroxyzine may provide valuable relief, easing the discomfort and supporting recovery. Remember, like a wise desert traveler, we must always seek compassionate and effective solutions to help those in need.

Date :
  1. Date Completed 2017-11-13
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27712113

DOI: Digital Object Identifier

NIHMS904160

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.